USFDA concludes cGMP inspection at Cipla’s Bangalore facility

27 Jan 2020 Evaluate

United States Food and Drug Administration (USFDA) has concluded a cGMP inspection at Cipla’s API manufacturing facility in Bommasandra, Bangalore from January 20 - 24, 2020. The inspection ended with 4 observations which were procedural in nature and none of which were repeat or related to data integrity.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1508.50 8.40 (0.56%)
02-Jan-2026 12:00 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1728.70
Dr. Reddys Lab 1248.85
Cipla 1508.50
Zydus Lifesciences 917.40
Lupin 2108.80
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×